Biomarker NTRK Coverage from Every Angle

John A. Bridgewater, MD, PhD, on Prognosis and Molecular Characteristics of Tumors With TRK Fusion

Posted: Sunday, August 1, 2021

John A. Bridgewater, MD, PhD, of University College London Cancer Institute, discusses findings from the 100,000 Genomes Project; the importance of the actionable driver TRK; and the clinical feasibility of testing for this alteration.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.